title: National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan.
abstract: BACKGROUND
  We surveyed the national experience of coronary artery bypass grafting (CABG) for coronary sequelae of Kawasaki disease (kDa) in 2002.
  
  
  RESULTS
  A questionnaire was returned from 323/552 (59%) institutions. Two hundred forty-four patients (188 male 56 female) since 1975 were identified. The mean number of grafts was 1.8 and the age at operation ranged from 1 to 44 years (median 11 years). The interval from the onset of kDa to operation ranged from 1 month to 42 years (median 8 years), whereas the follow-up period was from 7 days to 25 years (median 5 years). Previous myocardial infarction was found in 70 patients (28%). When the age at operation was older than 12 years, patency rates for internal thoracic artery grafts (ITA) at 1, 5, and 15 years were 95%, 91%, and 91%, respectively (n=156). When the age at operation was younger than 12 years, the corresponding values were significantly lower, with 1, 5, and 15 years being 93%, 73%, and 65%, respectively (n=146) (P<0.05). Reoperation was performed in 14 patients (6%). Death occurred in 15 patients (6%). Nine of the 14 late deaths were sudden. Six of 8 patients with a left ventricular ejection fraction (LVEF) <40% died.
  
  
  CONCLUSIONS
  The results of ITA in those aged 12 years or older were favorable. LVEF influenced prognosis.
authors.affiliation: Department of Pediatrics, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita-shi, Osaka, 565-8565, Japan. etsuda@hsp.ncvc.go.jp
authors.forename: Etsuko
authors.initials: E
authors.lastname: Tsuda
authors.forename: Soichiro
authors.initials: S
authors.lastname: Kitamura
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass / Q000706:statistics & numerical data*; D023903:Coronary Restenosis / Q000453:epidemiology / Q000628:therapy; D023921:Coronary Stenosis / Q000209:etiology / Q000601:surgery*; D003625:Data Collection; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000188:drug therapy / Q000601:surgery* / Q000628:therapy; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology / Q000601:surgery; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012086:Reoperation / Q000706:statistics & numerical data; D013318:Stroke Volume; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin